Suppr超能文献

系统评价和荟萃分析射频消融治疗低级别异型增生 Barrett 食管的疗效。

Systematic review and meta-analysis of the effectiveness of radiofrequency ablation in low grade dysplastic Barrett's esophagus.

机构信息

Department of Surgery, University Hospital of Wales, Cardiff, UK.

出版信息

Endoscopy. 2018 Oct;50(10):953-960. doi: 10.1055/a-0588-5151. Epub 2018 Apr 24.

Abstract

BACKGROUND

Barrett's esophagus (BE) is a premalignant condition characterized by replacement of the esophageal lining with metastatic columnar epithelium, and its management when complicated by low grade dysplasia (LGD) is controversial. This systematic review and meta-analysis aimed to determine the efficacy of radiofrequency ablation (RFA) in patients with LGD.

METHODS

MEDLINE, EMBASE, and Web of Science were searched for studies including patients with BE-associated LGD receiving RFA (January 1990 to May 2017). The outcome measures were complete eradication of intestinal metaplasia (CE-IM) and dysplasia (CE-D), rates of progression to high grade dysplasia (HGD) or cancer, and recurrence.

RESULTS

Eight studies including 619 patients with LGD (RFA = 404, surveillance = 215) were analyzed. After a median follow-up of 26 months (range 12 - 44 months), the overall pooled rates of CE-IM and CE-D after RFA were 88.17 % (95 % confidence interval [CI] 88.13 % - 88.20 %;  < 0.001) and 96.69 % (95 %CI 96.67 % - 96.71 %;  < 0.001), respectively. When compared with surveillance, RFA resulted in significantly lower rates of progression to HGD or cancer (odds ratio [OR] 0.07, 95 %CI 0.02 - 0.22). The pooled recurrence rates of IM and dysplasia were 5.6 % (95 %CI 5.57 - 5.63;  < 0.001) and 9.66 % (95 %CI 9.61 - 9.71;  < 0.001), respectively.

CONCLUSIONS

RFA safely eradicates IM and dysplasia and reduces the rates of progression from LGD to HGD or cancer in the short term.

摘要

背景

巴雷特食管(BE)是一种癌前病变,其特征是食管内层被转移性柱状上皮取代,当伴有低级别上皮内瘤变(LGD)时,其处理方法存在争议。本系统评价和荟萃分析旨在确定射频消融(RFA)治疗 LGD 患者的疗效。

方法

检索 MEDLINE、EMBASE 和 Web of Science 中 1990 年 1 月至 2017 年 5 月间发表的所有关于接受 RFA 治疗的 BE 相关 LGD 患者的研究。主要观察终点为完全消除肠化生(CE-IM)和异型增生(CE-D)、进展为高级别异型增生(HGD)或癌症的发生率以及复发率。

结果

共纳入 8 项研究,包括 619 例 LGD 患者(RFA 组 404 例,监测组 215 例),中位随访时间为 26 个月(范围 12-44 个月)。RFA 后,总体 CE-IM 和 CE-D 的完全消除率分别为 88.17%(95%置信区间 88.13%-88.20%;<0.001)和 96.69%(95%置信区间 96.67%-96.71%;<0.001)。与监测组相比,RFA 显著降低了进展为 HGD 或癌症的风险(比值比 [OR] 0.07,95%置信区间 0.02-0.22)。IM 和异型增生的复发率分别为 5.6%(95%置信区间 5.57%-5.63%;<0.001)和 9.66%(95%置信区间 9.61%-9.71%;<0.001)。

结论

RFA 能安全地消除 IM 和异型增生,并在短期内降低 LGD 进展为 HGD 或癌症的风险。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验